Literature DB >> 24821335

Cardiac electrical activity in a genomically "humanized" chromogranin a monogenic mouse model with hyperadrenergic hypertension.

Nagendu B Dev1, Saiful A Mir1, Jiaur R Gayen2, Jawed A Siddiqui1, Maja Mustapic1, Sucheta M Vaingankar1.   

Abstract

The prohormone chromogranin A (CHGA) is ubiquitously found in vesicles of adrenal chromaffin cells and adrenergic neurons, and it is processed to the hypotensive hormone peptide catestatin (CST). Both CHGA and CST regulate blood pressure and cardiac function. This study addresses their role in cardiac electrical activity. We have generated two genomically "humanized" transgenic mouse strains (Tg31CHGA+/+; Chga-/- (HumCHGA31) and Tg19CHGA+/+; Chga-/- (HumCHGA19)) with varied CHGA expression and the ability to rescue the Chga-/- phenotype (hypertensive, hyperadrenergic with dilated cardiomyopathy). The normotensive HumCHGA31 mice express CHGA at levels comparable to wild-type. In contrast, the hypertensive HumCHGA19 mice have low levels of CHGA. EKG recordings revealed that the QT interval, R-amplitude, and QRS time-voltage integral are markedly longer in HumCHGA19 compared to wild-type and HumCHGA31 mice. These differences are accompanied by increased heart rate and QT variability, indicating that ventricular assault happens in a status of low levels of circulating CST.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24821335      PMCID: PMC4101044          DOI: 10.1007/s12265-014-9563-7

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  43 in total

Review 1.  Errors and misconceptions in ECG measurement used for the detection of drug induced QT interval prolongation.

Authors:  Marek Malik
Journal:  J Electrocardiol       Date:  2004       Impact factor: 1.438

2.  Genetic influence on electrocardiogram time intervals and heart rate in aging mice.

Authors:  Shuqin Xing; Shirng-Wreng Tsaih; Rong Yuan; Karen L Svenson; Linda M Jorgenson; Milly So; Beverly J Paigen; Ron Korstanje
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-04-24       Impact factor: 4.733

3.  Cardiac hypertrophy in spontaneously hypertensive rats.

Authors:  S Sen; R C Tarazi; P A Khairallah; F M Bumpus
Journal:  Circ Res       Date:  1974-11       Impact factor: 17.367

4.  Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart.

Authors:  Saiful Anam Mir; Arunachal Chatterjee; Arkadeep Mitra; Kanchan Pathak; Sushil K Mahata; Sagartirtha Sarkar
Journal:  J Biol Chem       Date:  2011-12-07       Impact factor: 5.157

5.  Reprint of: Catestatin: a multifunctional peptide from chromogranin A.

Authors:  Sushil K Mahata; Manjula Mahata; Maple M Fung; Daniel T O'Connor
Journal:  Regul Pept       Date:  2010-10-20

6.  Subclinical cardiomyopathy in Becker muscular dystrophy.

Authors:  S E Steare; V Dubowitz; A Benatar
Journal:  Br Heart J       Date:  1992-09

7.  The trans-Golgi proteins SCLIP and SCG10 interact with chromogranin A to regulate neuroendocrine secretion.

Authors:  Nitish R Mahapatra; Laurent Taupenot; Maite Courel; Sushil K Mahata; Daniel T O'Connor
Journal:  Biochemistry       Date:  2008-06-13       Impact factor: 3.162

8.  Prognostic value of chromogranin A at admission in critically ill patients: a cohort study in a medical intensive care unit.

Authors:  Dan Zhang; Thomas Lavaux; Anne-Claire Voegeli; Thierry Lavigne; Vincent Castelain; Nicolas Meyer; Rémy Sapin; Dominique Aunis; Marie-Hélène Metz-Boutigue; Francis Schneider
Journal:  Clin Chem       Date:  2008-07-17       Impact factor: 8.327

9.  Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality.

Authors:  C Ceconi; R Ferrari; T Bachetti; C Opasich; M Volterrani; B Colombo; G Parrinello; A Corti
Journal:  Eur Heart J       Date:  2002-06       Impact factor: 29.983

10.  Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart.

Authors:  Claudia Penna; Giuseppe Alloatti; Maria Pia Gallo; Maria Carmela Cerra; Renzo Levi; Francesca Tullio; Eleonora Bassino; Serena Dolgetta; Sushil K Mahata; Bruno Tota; Pasquale Pagliaro
Journal:  Cell Mol Neurobiol       Date:  2010-11-23       Impact factor: 5.046

View more
  3 in total

Review 1.  Role of Catestatin in the Cardiovascular System and Metabolic Disorders.

Authors:  Ewa Zalewska; Piotr Kmieć; Krzysztof Sworczak
Journal:  Front Cardiovasc Med       Date:  2022-05-19

2.  Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT-HF study.

Authors:  Josip A Borovac; Duska Glavas; Zora Susilovic Grabovac; Daniela Supe Domic; Lada Stanisic; Domenico D'Amario; Chun S Kwok; Josko Bozic
Journal:  ESC Heart Fail       Date:  2020-07-18

Review 3.  Catestatin as a Biomarker of Cardiovascular Diseases: A Clinical Perspective.

Authors:  Josko Bozic; Marko Kumric; Tina Ticinovic Kurir; Hrvoje Urlic; Dinko Martinovic; Marino Vilovic; Nada Tomasovic Mrcela; Josip A Borovac
Journal:  Biomedicines       Date:  2021-11-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.